About immuneering corp - IMRX
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
IMRX At a Glance
Immuneering Corp.
245 Main Street
Cambridge, Massachusetts 02142
| Phone | 1-617-500-8080 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -56,024,898.00 | |
| Sector | Health Technology | Employees | 37 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IMRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.947 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.055 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.032 |
IMRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,514,186.432 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IMRX Liquidity
| Current Ratio | 17.496 |
| Quick Ratio | 17.496 |
| Cash Ratio | 17.157 |
IMRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -39.357 |
| Return on Equity | -43.118 |
| Return on Total Capital | -25.201 |
| Return on Invested Capital | -41.947 |
IMRX Capital Structure
| Total Debt to Total Equity | 1.75 |
| Total Debt to Total Capital | 1.72 |
| Total Debt to Total Assets | 1.649 |
| Long-Term Debt to Equity | 1.569 |
| Long-Term Debt to Total Capital | 1.542 |